Document:

EX-4.5                                    CERTIFICATE OF DESIGNATION

                         CERTIFICATE OF DESIGNATION
                                     OF
                              NATIONS RX, INC.

The undersigned, David Rykbos, President/Secretary, certifies that:

He is the President and Secretary of Nations Rx, Inc., a Nevada
corporation ("Company").

By action of the Board of Directors of the Company on June 30, 2003,
at the Company's offices located at 8 Macbeth Court, Rancho Mirage,
California 92270, the following resolution was adopted by unanimous
written consent of the Directors:

WHEREAS, Article IV of the Articles of Incorporation of the Company,
as amended, authorizes the Company to issue Ten Million (10,000,000)
shares of preferred stock, par value of One Tenth of One Cent
($0.001) per share ("Preferred Stock"); and

WHEREAS, the shares of Preferred Stock were authorized to be issued
from time to time in one or more series as expressly authorized by
the Board of Directors to determine or alter the rights, preferences,
privileges, and restrictions granted to or imposed on any wholly
unissued class of shares or any wholly issued series of any class of
shares, and the number of shares constituting any unissued series of
Preferred Stock as well as the designations of the series, or any or
all of them.

NOW, THEREFORE, BE IT RESOLVED, that the Board of Directors does
hereby provide for the issue of undesignated Preferred Stock of the
Company and does hereby fix and determine the rights, preferences,
privileges, and restrictions of, and other matters relating to, that
series, as follows:

Six Million (6,000,000) shares of undesignated and unissued Preferred
Stock shall be designated and known as "Series A Convertible
Preferred Stock", par value One Tenth of One Cent ($0.001), with the
powers, preferences, rights, restrictions, and other matters as
follows.

(1)        CONVERSION.  The holders of Series A Convertible Preferred
Stock shall have conversion rights as follows (the "Conversion
Rights"):

     (a)  Any securities to be delivered to the holders of Series A
     Convertible Preferred Stock pursuant to this Section shall be
     valued as follows ("Valuation Price"):

        (i)  Securities not subject to investment letter or other
        similar restrictions on free marketability:

          (A)  If traded on a securities exchange, the value
          shall be deemed to be the average of the closing
          prices of the securities on such exchange over the
          thirty (30) day period ending three (3) days prior to
          the closing;

          (B)  If actively traded over-the-counter, the value
          shall be deemed to be the average of the closing bid
          and asked prices over the thirty (30) day period
          ending three (3) days prior to the closing; and

          (C)  If there is no active public market, the value
          shall be the fair market value thereof, as determined by the Company.

        (ii)  The method of valuation of securities subject to
        investment letter or other restrictions on free
        marketability shall be to make, an appropriate discount
        from the market value determined as above in clauses
        (i)(A), (B) or (C) to reflect the approximate fair market
        value thereof, as determined by the Company.

     (b)  Right to Convert by the Company.  Subject to subsection
     (c), each share of outstanding Series A Convertible Preferred
     Stock shall be convertible, at the option of holder, at any time
     into six (6) fully paid and nonassessable shares of Company
     common stock ("Common Stock") ("Conversion Rate").

     (c)  Mechanics of Conversion.

        (i)  Before any holder of Series A Convertible Preferred
        Stock shall be entitled voluntarily to convert the same
        into shares of Common Stock, he/she/it shall surrender the
        certificate or certificates therefor, duly endorsed, at the
        office of the Company or of any transfer agent for such
        stock, and shall give written notice to the Company at such
        office that he/she/it elects to convert the same and shall
        state therein the number of shares to be converted and the
        name or names in which he/she/it wishes the certificate or
        certificates for shares of Common Stock to be issued.  The
        Company shall, as soon as practicable thereafter, issue and
        deliver at such office to such holder of Series A
        Convertible Preferred Stock, a certificate or certificates
        for the number of shares of Common Stock to which he shall
        be entitled.  Such conversion shall be deemed to have been
        made immediately prior to the close of business on the date
        or surrender of the shares of Series A Convertible
        Preferred Stock to be converted, and the person or persons
        entitled to receive the shares of Common Stock issuable
        upon such conversion shall be treated for all purposes as
        the record holder or holders of such shares of Common Stock
        on such date.

        (ii)  If the conversion is in connection with an
        underwritten offering of securities pursuant to the
        Securities Act, the conversion may, at the option of any
        holder tendering shares of Series A Convertible Preferred
        Stock for conversion, be conditioned upon the closing with
        the underwriters of the sale of securities pursuant to such
        offering, in which event the person(s) entitled to receive
        the Common Stock upon conversion of the Series A
        Convertible Preferred Stock shall not be deemed to have
        converted such Series A Convertible Preferred Stock until
        immediately prior to the closing of such sale of securities.

     (d)  Adjustments to Conversion Rate In the case of any share
     exchange, capital reorganization, consolidation, merger or
     reclassification whereby the Common Stock is converted into
     other securities or property, the Company will make appropriate
     provisions so that the holder of each share of Class A Preferred
     Stock then outstanding will have the right thereafter to convert
     such share of Class A Preferred Stock into the kind and amount
     of shares of stock and other securities and property receivable
     upon such consolidation, merger, share exchange, capital
     reorganization or reclassification by a holder of the number of
     shares of Common Stock into which such shares of Class A
     Preferred Stock might have been convened immediately prior to
     such consolidation, merger, share exchange, capital
     reorganization or reclassification.  If the shares of Common
     Stock are subdivided or combined into a greater or smaller
     number of shares of Common Stock, the Conversion Ratio shall be
     proportionately increased in case of subdivision of shares.  If
     the shares of Common Stock are combined, consolidated or reverse
     split into a smaller number of shares of Common Stock the
     Conversion Ratio shall not be decreased.  The kind and amount of
     Common Shares issuable upon conversion of the Class A Preferred
     Stock both before and after combination, consolidation or
     reverse split of the Common Shares shall be the same.

     (e)  No Impairment.  The Company will not, by amendment of its
     Articles of Incorporation or through any reorganization,
     transfer of assets, consolidation, merger, dissolution, issue or
     sale of securities or any other voluntary action, avoid or seek
     to avoid the observance or performance of any of the terms to be
     observed or performed hereunder by the Company, but will at all
     times in good faith assist in the carrying out of all the
     provisions of this Section and in the taking of all such action
     as may be necessary or appropriate in order to protect the
     Conversion Rights of the holders of the Series A Convertible
     Preferred Stock against impairment.

     (f)  Certificates as to Adjustments.	Upon the occurrence of
     each adjustment or readjustment of any Conversion Rate pursuant
     to this Section, the Company, at its expense shall promptly
     compute such adjustment or readjustment in accordance with the
     terms hereof and prepare and furnish to each holder of Series A
     Convertible Preferred Stock a certificate executed by the
     Company's President or Chief Financial Officer setting forth
     such adjustment or readjustment and showing in detail the facts
     upon which the Company shall, upon the written request at any
     time of any holder of Series A Convertible Preferred Stock,
     furnish or cause to be furnished to such holder a like
     certificate setting forth (i) such adjustments and
     readjustments, (ii) the Conversion Rate at the time in effect,
     and (iii) the number of shares of Common Stock and the amount if
     any, of other property which at the time would be received upon
     the conversion of the Series A Convertible Preferred Stock.

     (g)  Notices of Record Date.  In the event that the Company
     shall propose at any time: (i) to declare any dividend or
     distribution upon its Common Stock, whether in cash, property,
     stock or other securities. whether or not a regular cash
     dividend and whether or not out of earnings or earned surplus;
     (ii) to offer for subscription pro rata to the holders of any
     class or series of its stock any additional shares of stock of
     any class or series or other rights; (iii) to effect any
     reclassification or recapitalization of its Common Stock
     outstanding involving a change in the Common Stock; or (iv) to
     merge or consolidate with or into any other corporation, or
     sell, lease or convey all or substantially all of its assets, or
     to liquidate, dissolve or wind up; then, in connection with each
     such event, the Company shall send to the holders of Series A
     Convertible Preferred Stock:

        (i)  At least twenty (20) days prior written notice of the
        date on which a record shall be taken for such dividend,
        distribution or subscription rights (and specifying the
        date on which the holders of Common Stock shall be entitled
        thereto) or for determining rights to vote, if any, in
        respect of the matters referred to in (iii) and (iv) above;
        and

        (ii)  In the case of the matters referred to in (iii) and
        (iv) above, at least twenty (20) days prior written notice
        of the date when the same shall take place (and specifying
        the date on which the holders of Common Stock shall be
        entitled to exchange their Common Stock for securities or
        other property deliverable upon the occurrence of such
        event).

     (h)  Reservation of Stock lssuable Upon Conversion.  The
     Company shall at all times reserve and keep available out of its
     authorized but unissued shares of Common Stock, solely for the
     purpose of effecting the conversion of the shares of the Series
     A Preferred Stock, such number of its shares of Common Stock as
     shall from time to time be sufficient to effect the conversion
     of all outstanding shares of the Series A Convertible Preferred
     Stock; and if at any time the number of authorized but unissued
     shares of Common Stock shall not be sufficient to effect the
     conversion of all then outstanding shares of the Series A
     Convertible Preferred Stock, the Company will take such
     corporate action as may, in the opinion of its counsel, be
     necessary to increase its authorized but unissued shares of
     Common Stock to such number of shares as shall be sufficient for
     such purpose, including, without limitation, engaging in best
     efforts to obtain the requisite stockholder approval of any
     necessary amendment to this Certificate.

        (i)  Fractional Shares.  No fractional share shall be issued
        upon the conversion of any share or shares of Series A
        Convertible Preferred Stock.  All shares of Common Stock
        (including fractions thereof) issuable upon conversion of more
        than one share of Series A Convertible Preferred Stock by a
        holder thereof shall be aggregated for purposes of determining
        whether the conversion would result in the issuance of any
        fractional share.  If, after the aforementioned aggregation, the
        conversion would result in the issuance of a fraction of a share
        of Common Stock, the Company shall, in lieu of issuing any
        fractional share, pay the holder otherwise entitled to such
        fraction a sum in cash equal to the fair market value of such
        fraction on the date of conversion (as determined in good faith
        by the Board of Directors).

     (j)  Notices.  Any notice required to be given to the holders of
     shares of Series A Convertible Preferred Stock shall be deemed
     given if deposited in the United States mail, postage prepaid,
     and addressed to each holder of record at his address appearing
     on the books of the Company.

(2)  VOTING RIGHTS.  The holder of each share of Series A Convertible
Preferred Stock shall have the right to one vote for each share of
Common Stock into which such share of Series A Convertible Preferred
Stock could be converted on the record date for the vote or written
consent of stockholders.  In all cases any fractional share,
determined on an aggregate conversion basis, shall be rounded to the
nearest whole share.  With respect to such vote, such holder shall
have full voting rights and powers equal to the voting rights and
powers of the holders of Common Stock, and shall be entitled,
notwithstanding any provision hereof, to notice of any stockholders
meeting in accordance with the bylaws of the Company, and shall be
entitled to vote, together with holders, of Common Stock, with
respect to any question upon which holders of Common Stock have the
right to vote,

(3)  STATUS OF CONVERTED STOCK.  In the event any shares of Series A
Convertible Preferred Stock shall be converted pursuant to Section 1
hereof, the shares so converted shall be canceled and shall not be
issuable by the Company, and all such shares shall be canceled,
retired and eliminated from the shares that the Company is authorized
to issue.

(4)  SENIORITY OF SERIES A CONVERTIBLE PREFERRED STOCK. No additional
shares of Series A Convertible Preferred Stock shall be authorized or
issued that have rights, privileges and preferences equal to or
senior to the Series A Convertible Preferred Stock as long as any
Series Convertible Preferred Stock is outstanding.

(5)  RESTRICTIONS AND LIMITATIONS.  So long as any shares of Series
Convertible Preferred Stock remain outstanding, the Company shall
not, without the vote or written consent by the holders of at least a
majority of the then outstanding shares of Series A Convertible
Preferred Stock, amend these Articles of Incorporation if such
amendment would adversely affect any of the rights, preferences or
privileges provided for herein for the benefit of the Series A
Convertible Preferred Stock.

(6)  DIVIDENDS ON PREFERRED STOCK.  The Company shall, in its
discretion, determine when and if dividends will be paid, and whether
it will be paid in cash, shares of Common Stock, or a combination of
both. All Series A Convertible Preferred Stock shall be treated the
same with respect to the payment of dividends as the holders of the
Common Shares. In the event the Company elects to pay a portion or
all of the dividends on the Series A Convertible Preferred Stock by
issuing shares of the Company's Common Stock, the shares of common
stock issued as dividends will be restricted, unregistered shares,
and will be subject to the same transfer restrictions that apply to
the shares of Series A Convertible Preferred Stock. The dividend is
payable as may be determined by the Board of Directors, out of funds
legally available therefor.  The Series A Convertible Preferred Stock
will not have priority as to dividends over the Common Stock and will
rank pari passu.

(7)  TRANSFER RESTRICTIONS.  The same transfer restrictions imposed
on the Class A Preferred Stock shall be applicable to the Common
Stock into which the Class A Preferred Stock is converted, although
for purposes of Rule 144 as presently in effect, the holding period
requirement may be met by adding together the period in which the
Class A Preferred Stock is held and the period in which the Common
Stock into which the Class A Preferred Stock is converted, is held.

(8)  LIQUIDATION RIGHTS.  In case of the voluntary or involuntary
liquidation, dissolution or winding-up of the Company, holders of
Shares of the Series A Convertible Preferred Stock are entitled to
receive a liquidation preference of one dollar ($1.00) per share
before any payment or distribution is made to the holders of Common
Stock or any other series or class of the Company's stock hereafter
issued which ranks junior as to liquidation rights to the Series A
Convertible Preferred Stock. A consolidation or merger of the Company
with another corporation will be deemed to be a liquidation,
dissolution or winding-up of the Company unless the Company is the
surviving corporation and its shareholders immediately prior to the
consolidation or merger are the holders of at least fifty-one percent
(51%) of the voting equity of the surviving corporation immediately
after the consolidation or merger. A sale or transfer of all or part
of the Company's assets for cash, securities or other property will
not be considered a liquidation, dissolution or winding-up of the
Company.

Holders of shares of any Series A Convertible Preferred Stock issued
in the future shall be entitled to receive a liquidation preference
of one dollar ($1.00) per share, before any payment or distribution
is made to the holders of Common Stock or any other series or class
of the Company's stock hereafter issued which ranks junior as to
liquidation rights to the Series A Convertible Preferred Stock. To
the extent any payment or distribution is insufficient to pay the
entire liquidation preference on all outstanding shares of Series A
Convertible Preferred Stock, the payment shall be apportioned pro
rata among the holders of the Series A Convertible Preferred Stock.

RESOLVED FURTHER, that the Secretary of the Company is hereby
authorized and directed to prepare, execute, verify and file, in the
office of the Nevada Secretary of State, a Certificate of Designation
in accordance with this resolution as required by law.

NATIONS RX, INC.

By: /s/  David Rykbos                  Date: June 30, 2003
David Rykbos, President/SecretaryExhibit 10.2                               Master Sales Associate Agreement

This Agreement  (the Agreement) entered into this 6th day of June,
2003, between NationsRx, Inc. ("NationsRx"), a Nevada corporation
with corporate offices at 23905 Clinton Keith Road, Suite 114-201,
Wildomar, CA 92595 and MEDSTRONG INTERNATIONAL CORPORATION
("Associate"), a Delaware corporation, with its principal office
located at 500 Silver Spur Road, Third Floor, Rancho Palos Verdes,
California 90274,.

WITNESSETH

Whereas, NationsRx markets, sells, and licenses healthcare products
and services in the pharmacy benefit sector ("Product").

Whereas, NationsRx wishes to cooperate with the Associate to identify
Registered Qualified Prospects, and identify sub-distributors
(hereinafter " Sub-Distributors"") who would like to market the
Company's Product and Associate desires to identify and Registered
Qualified Prospects and Sub-Distributors that wish to utilize or
market the Product.

Now therefore, in consideration of the mutual promises given
hereunder, the parties hereto do agree as follows:

1).  DEFINITIONS.

     a.  The term "Confidential Information" shall mean all information
         and materials disclosed by one Party to the other, whether
         before or after the date hereof, respecting, comprising,
         describing, embodying or incorporating:

       (i)  Documentation, data bases, data processing or
            communications networking systems, practices or procedures
            or other internal systems or controls (planned or in any
            stage of development) of NationsRx or it's affiliated
            companies , and

       (ii) Other technical data, research, products, business or
            financial information, plans or strategies, forecasts or
            forecast assumptions, business practices, operations or
            procedures, services, marketing or merchandising
            information respecting NationsRx, and their customers.

     b.  The term "Product" shall mean the products and services of
         NationsRx and it's affiliated companies,

     c.  The term "Effective Date" shall mean the date first written above.

     d.  The term "Registered Qualified Prospect" shall be a person or
         entity that has been registered by written mutual agreement
         between NationsRx and the Associate pursuant to Schedule 1.

     e.  The term "End-User" shall mean a member who has acquired the
         Products from a Associate, Sub-Distributor or NationsRx for
         their own use in accordance with the terms and conditions of
         the standard purchase order and not for redistribution,
         remarketing or service bureau use.

     f.  "Marks" means trademarks, copyrights and logo's that are from
         time to time applicable to the Product, including applications
         for such trademarks and unregistered trademarks of NationsRx.

2).  TERM.  The term of this Agreement shall commence on the
Effective Date and shall continue in force for one (1) year (the
Initial Term).  At the end of such Initial Term, if not terminated by
either party by giving at least sixty days prior written notice, this
Agreement shall be renewed automatically each year thereafter for an
additional term of one (1) year unless and until terminated as
provided herein.

3).  ASSOCIATE'S OBLIGATIONS.  During the term of this Agreement,
Associate shall have the following obligations:

     (a)  Utilize its best efforts to help NationsRx penetrate the
          designated health care pharmacy benefit markets as mutually defined
          with the Product by identifying persons or entities as Sub-
          Distributors, End-Users or Registered Qualified Prospects;

     (b)  Present to NationsRx all available information concerning a
          qualified prospect via Schedule 1.  NationsRx will review Schedule
          1 within 3 business days following receipt and determine whether
          such person or entity should be recognized as a Registered
          Qualified Prospect.  NationsRx reserves the right, in its sole
          discretion, to decline the registration of any person or entity
          proposed by the Associate as a Registered Qualified Prospect for
          any reason, including the fact that the person or entity has
          previously been recognized as a prospect to utilize the Product by
          NationsRx itself a NationsRx Sub-distributor, or by another Associate.

     (c)  If NationsRx accepts the registration of a qualified prospect as
          a Registered Qualified Prospect, Associate shall then utilize its
          best efforts to introduce NationsRx officers and employees to the
          respective officers or employees of the Registered Qualified
          Prospect who can make or influence the decision to utilize the
          Product;

     (d)  If NationsRx accepts the registration of a person or entity as a
          Registered Qualified Prospect, Associate shall not collaborate or
          attempt to collaborate with any other third party for the purpose
          of sales and marketing of a competing pharmacy benefit program to
          the Registered  Qualified Prospect.

4).  MARKETING EFFORT.  NationsRx shall supply Associate with
reasonable amounts of Product literature.  Associate shall provide
Registered Qualified Prospects with Product literature provided by
NationsRx or its affiliates only.  Any and all advertising,
promotional material or other materials developed by the Associate is
subject to the prior written approval by NationsRx before
distribution to any third parties.  Both NationsRx and the Associate
shall have the right but not an obligation to disclose the
relationship between the parties to End-User's.

5).  ASSOCIATE COMPENSATION.  In the event that NationsRx or a
NationsRx Associate is successful in Product sale(s), the Associate
will be entitled to payment of the commission from NationsRx as
specified on Schedule 2.

6).  TRADEMARKS, Etc.   Subject to the terms and conditions hereof
and effective only during the term of this Agreement, Associate may
display, apply and use the Marks for the Product, and such other
related or derivative word devices as NationsRx may in writing permit
the Associate to display and use provided that each use of Marks is
first approved by NationsRx.

7).  DISPUTES AMONG ASSOCIATES, DEALERS, AND OTHER DISTRIBUTORS.
NationsRx shall have the sole authority and discretion to settle any
disputes between Associate and NationsRx's other Associates and Sub-
distributor(s) of the Product, provided that such settlement is
consistent with the terms of this Agreement.

8).   INDEMNIFICATION.  Associate does hereby indemnify and hold
NationsRx harmless against any claim, cost, expense (including
attorney's fees) or liability of every kind with respect to any claim
or suit by a third-party by reason of Associate's actions, omissions,
or breach of this Agreement.

9). CONFIDENTIAL INFORMATION.

     (a)  Both Parties shall use reasonable efforts to protect any
          Confidential Information disclosed to it by the other Party from
          unauthorized disclosure or use, using at least the same level of
          care as it uses to protect its own confidential information.
          Subject to the foregoing, and except as may be specifically
          agreed from time to time by the Parties, either Party shall not
          (i) communicate or disclose, directly or indirectly, any of the
          Confidential Information (or any part thereof) to any Person
          other than its own personnel who have a need for such
          information in connection with the performance under this
          Agreement, or (ii) use any Confidential Information (or any part
          thereof) in any manner except as contemplated under this
          Agreement, or (iii) take any other action with respect to the
          Confidential Information (or any part thereof) inconsistent with
          the confidential and proprietary nature of such information.

     (b)  Neither Party shall make or use more copies of any
          Confidential Information than it shall reasonably deem necessary
          in connection with its permitted use thereof.  Both Parties
          shall retain on its premises Confidential Information of the
          other Party and shall not move any tangible embodiment of such
          Confidential Information from its premises without express
          written consent of the other Party.

     (c)  The Parties agree that any use that is made of Confidential
          Information in the course of performance of, and to the extent
          permitted by, the provisions of this Agreement shall not, in and
          of itself, constitute a violation of the provisions of this
          Section 9.  Disclosure of any Confidential Information by either
          Party, however, shall not be deemed to represent an assignment
          or grant of any right, title or interest in such Confidential
          Information to the receiving Party.

     (d)  No provision of this Section 9 shall prohibit disclosure by
          either Party of any information or materials that (i) are or
          become generally available to the public other than as a result
          of any breach of the provisions of this Agreement, (ii) are in
          the possession of such Party prior to receipt pursuant to this
          Agreement (other than through any improper means) and are not
          subject to a confidentiality obligation between the Parties,
          (iii) are commonly known to Persons that are not Affiliates,
          officers, agents, employees or contractors of the Parties
          engaged in the health care industries or by individuals employed
          by persons engaged in such industries other than as a result of
          any breach of the provisions of this Agreement or any other
          applicable agreement between the parties hereto, (iv) are
          independently developed by such Party without reference to the
          Confidential Information of the other Party hereto, or (v) are
          required to be disclosed by such Party under any applicable law,
          regulation or final order of any Governmental Authority (in
          which case such Party shall promptly give notice to the other
          Party of such required disclosure, describing in reasonable
          specificity and detail all Confidential Information to be so
          disclosed and all relevant circumstances with respect to such
          disclosure, to enable the other Party to take any appropriate
          action in order to limit such required disclosure, and shall
          provide all reasonable cooperation to the other Party, at the
          other Party's expense, in connection with any such action).

10).  TERMINATION OF AGREEMENT.  The non-breaching party may
terminate this Agreement:

     a).  in the event Associate or NationsRx breaches any term of
          this Agreement and fails to cure the breach within thirty (30)
          days after notice; or

     b).  in the event Associate or NationsRx shall cease doing
          business, file a bankruptcy petition or make an assignment for
          the benefit of creditors; or

     c).  upon ninety (90) days written notice by one party to the
          other, with or without cause.

Immediately upon termination, Associate shall cease all activities
concerning Product and shall return to NationsRx all unused Product
literature, operating manuals, and any other Confidential
Information.  All other obligations, except each party's agreements
as to payment for purchases, confidentiality, and indemnification,
shall terminate.

11).  HEADINGS.  The headings contained herein are merely for
references and purposes of organization and shall not be used to
interpret this Agreement.

12).  ENTIRE AGREEMENT.  This Agreement is the sole and complete
statement of the parties of their rights and obligations.  This
Agreement replaces and supersedes any and all previous agreements
between the parties including written and verbal understandings.  Any
amendments shall be in writing, and executed by authorized
representatives of each respective party.  Neither party may assign
its rights or obligations without the prior written consent of the
other party.

13).  SEVERABILITY.  If any provision of this Agreement shall be held
illegal, unenforceable, or in conflict with any law, the validity of
the remaining portions or provisions hereto shall not be affected
thereby.

14).  FORCE MAEJURE.  Neither party shall be in default if failure to
perform any obligation hereunder is caused solely by supervening
conditions (e.g., acts of God) beyond that party's control.

15).  NOTICES.  All notices under this Agreement shall be deemed duly
given upon delivery, if delivered by hand (against receipt) or three
(3) days after posting, if sent by certified mail or overnight
courier, return receipt requested, at the address specified at each
party's signature hereto or such other address as the parties shall
advise each other in writing from time to time.

16).  CONSENT TO BREACH NOT WAIVER.  No term or provision hereof
shall be deemed waived and no breach excused, unless such waiver or
consent shall be in writing and signed by the party claimed to have
waived or consented.   Any consent by either party to, or waiver of,
a breach by the other, whether expressed or implied, shall not
constitute consent to, a waiver of, or excuse for other different or
subsequent breach.

17).  AUTHORITY.  Each party has full power and authority to enter
into and perform this Agreement, and the person signing this
Agreement on behalf of each has been properly authorized and
empowered to enter into this Agreement.

18).  INDEPENDENT CONTRACTOR.  Associate is an independent contractor
under this Agreement and nothing herein shall be construed to create
a partnership, employee/employer, joint venture, or agency
relationship between the parties.  Associate shall have no authority
to enter into agreements of any kind on behalf of NationsRx or its
affiliates.  Unless otherwise specified in this Agreement, each party
shall bear its own expenses relating to activities under this
Agreement.

19).  GOVERNING LAW AND FORUM.  This Agreement, its terms and
conditions, and all business conducted hereunder shall be governed
and interpreted under the laws of the State of Nevada.  By mutual
agreement of the parties hereto, any dispute may be submitted to
binding arbitration in the City of Riverside under the rules then
prevailing of the American Arbitration Association.

IN WITNESS WHEREOF, the parties do hereby sign, enter into and
acknowledge this Agreement.

NationsRx, Inc.:                       Associate:

By:                                    By:
David A. Rykbos
Title:  President                      Title:
Date:                                  Date:

SCHEDULE 1
REQUEST FOR Registered Qualified Prospect

Name of Qualified Prospect:

Address:

Description of business:

Associate submitting this request:

Signature and date of Associate submission:

NationsRx, Inc. declines Registration for the following reason:

2.  NationsRx, Inc.
3.  Director / Operations

NationsRx agrees that the above Qualified Prospect shall become a
Registered  Qualified Prospect as of this           day of
2003 (the "REGISTRATION DATE").

4.  David A. Rykbos
5.  President, NationsRx, Inc.
6.

Schedule 2
Discounts / Commissions

FOR ASSOCIATE Product SALES:

Within fifteen (15) days after each month end in which NationsRx
receives the payment of invoice for associate referred client(s)
product purchases, NationsRx shall pay to Associate a commission
equal to:

     a)  an amount of $6.00 for each individual pharmacy benefit
     plan (PBP) sold and $9.00 for each family pharmacy
     benefit plan sold.  For the same period of this
     agreement, for all renewal plans sold, NationsRx shall
     pay Associate 50% of the initial commission for the first
     renewal year and 25% of the initial commission for each
     subsequent year.

     b)  An amount of 20% of the net profit generated through the
     user of the NationsRx Products by any Registered
     Qualified Prospects

No discounts / commissions or any other form of compensation shall
be paid / offered on other products and services as offered or
performed by NationsRx.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]